Influenza Therapeutics Market Provide Pipeline Review, Product Analysis and Forecasts To 2022

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. APAC region is an attractive market for seasonal influenza vaccine manufacturers. Continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

Browse Detail Report With TOC @ http://www.hexareports.com/report/seasonal-influenza-therapeutics-in-asia-pacific-markets-to-2022

Analysis shows that the R&D pipeline for seasonal influenza vaccines comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. GBI Research expects that quadrivalent seasonal influenza vaccines will replace their trivalent vaccines forerunner by the end of the forecast period.

Request A Sample copy of This Report @ http://www.hexareports.com/report/seasonal-influenza-therapeutics-in-asia-pacific-markets-to-2022/request-sample

Scope
* The seasonal influenza Asia-Pacific market will be valued at $1.71 billion in 2022, growing from $1.24 billion in 2015 at a CAGR of 4.7%.
* Trivalent and quadrivalent vaccines dominate the seasonal influenza market, but unmet needs exist in terms of safety and efficacy.
* Will the drugs under development fulfill the unmet needs of the seasonal influenza market?
* Do quadrivalent therapies show continuous growth, and are they facing any competition from trivalent therapies?
* How will available therapies be affected by upcoming pipeline therapies?
* The pipeline contains a range of molecule types and molecular targets, including those that are well established in seasonal influenza.
* Which molecular targets appear most frequently in the pipeline?
* Will the pipeline drugs fulfill the unmet needs of seasonal influenza market?
 
Reasons to buy

This report will allow you to –
1. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
2. Visualize the composition of the seasonal influenza market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
3. Analyze the seasonal influenza pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
4. Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
 
Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Antibacterial Therapies Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/antibacterial-therapies-drug-development-pipeline-review-2017

• Cardiovascular Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/cardiovascular-disorders-drug-development-pipeline-review-2017

• Global Cancer Vaccines Market to 2022 -
http://www.hexareports.com/report/global-cancer-vaccines-market-to-2022

Melanoma Market Scope, Trends, Key Vendor Analysis and Forecast by 2022

Melanoma is a form of cancer that begins in the melanin producing cells and commonly occurs in pigmented skin tissue such as moles – a form referred to as cutaneous melanoma. It can also affect several other pigmented tissues of the body. Increasing global incidence over recent decades is thought to be due to an increase in exposure to UV light and/or sunlight.

The disease is divided into two categories based on how advanced it is upon diagnosis. These are early-stage melanoma, which can be treated with surgery, and advanced melanoma, which cannot. Therapeutic options differ between the two treatment settings, with early-stage therapy aiming to prevent disease re-occurrence, and advanced therapies aiming to slow disease progression while maintaining the patient’s quality of life (QoL). Unmet need remains in the form of improving the efficacy of treatment options and patient QoL.

This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the melanoma market, with additional focus on the late-stage pipeline.

Browse Detail Report With TOC @
http://www.hexareports.com/report/melanoma-heat-map-and-analysis

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Request A Sample copy of This Report @
http://www.hexareports.com/report/melanoma-heat-map-and-analysis/request-sample

Scope
* How is the melanoma market landscape expected to change with regard to therapeutic type, due to promising pipeline therapies?
* What are the clinical characteristics of currently approved therapies for melanoma, in terms of specific safety and efficacy parameters?
* How are clinical safety and efficacy parameters linked to the key unmet needs in this indication?
* How will current late-stage combination therapeutics affect the melanoma market, and will they be able to satisfy current unmet need with regard to safe therapy options?
* Will the repositioning of currently approved metastatic melanoma drugs prove beneficial for patients in the adjuvant setting?
* Will recent first-in-class market approvals impact the market significantly?

Reasons To Buy
1. Understand the current clinical landscape by considering the treatment options available for each patient segment.
2. Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
3. Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
4. Understand the relative strengths and weaknesses of the studies used to gather these data.
5. Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
6. Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Global Cancer Immunotherapies Market to 2022 -
http://www.hexareports.com/report/global-cancer-immunotherapies-market-to-2022

• Frontier Pharma: Hepatitis C – Diverse Range -
http://www.hexareports.com/report/frontier-pharma-hepatitis-c

• Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 -
http://www.hexareports.com/report/hemophilia-a-and-b-therapeutics-in-asia-pacific-markets-to-2022

Respiratory Drugs Market Provide Consumption Patterns, Market Dynamics and Investment Feasibility Analysis to 2022

The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

Browse Detail Report With TOC @
http://www.hexareports.com/report/global-respiratory-drugs-market-to-2022

However, over the past decade the treatment of respiratory disorders has developed significantly, as has the importance for novel therapies and targeted therapies. The approval of the products Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment options for CF. Another important entry was the first biologic drug – omalizumab – approved in 2014 for the treatment of severe asthma. The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.

Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are currently in active in development for respiratory disorders.

Request A Sample copy of This Report @
http://www.hexareports.com/report/global-respiratory-drugs-market-to-2022/request-sample

Scope
* The respiratory disorders market is characterized by entrenched, commercially successful therapies.
* Which classes of drug dominate the market?
* What additional benefits have newly approved therapies brought to the market?
* What are the future prospects for the leading brands?
* The pipeline contains a range of molecule types and molecular targets, with a growing presence of targeted therapies.
* Which molecular targets appear most frequently in the pipeline?
* What are the commercial prospects for the most promising late-stage pipeline products?
* Respiratory disorders clinical trials have an overall attrition rate of 89.1%.
* What are the failure rates at individual phases of clinical development?
* How do the key respiratory disorders compare in terms of clinical trial failure rate?
* The respiratory disorders market is forecast to rise from a value of $28.1 billion in 2015 to $46.6 billion in 2022, at a CAGR of 7.5%.
* How much of a role will pipeline product approvals play in market growth?
* Are the large number of recently approved products expected to drive market growth?
* Will generic competition have a significant impact on the market over the forecast period?
* Which products face generic competition?
 
Reasons To Buy

This report will allow you to -
1. Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in respiratory disorders.
Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
2. Analyze the respiratory disorders pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
3. Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
4. Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory disorder products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 -
http://www.hexareports.com/report/non-small-cell-lung-cancer-therapeutics-in-asia-pacific-markets-to-2023

• Diabetes & Obesity Drug Development Pipeline Review, 2016 -
http://www.hexareports.com/report/diabetes-and-obesity-drug-development-pipeline-review-2016

• Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 -
http://www.hexareports.com/report/Anti-hypertensive-therapeutics-in-asia-pacific-markets-to-2022

Ophthalmology Drugs Market Size, Scope, Overview, Drivers and Key Vendor Analysis by 2022

Ophthalmology is a therapy area that deals with the diagnosis, treatment and prevention of diseases associated with the eyes and visual system. Most eye disorders occur over a long period of time, and are initially asymptomatic or cause only a slight decrease in vision. However, over time this becomes quite marked. Ophthalmologic disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

Angiogenesis inhibitors are the most effective and most common therapies used in ophthalmology; this class of compounds has been the most commercially successful in the past decade, with products such as Eylea and Lucentis generating strong annual revenues. Although there are many generics available across the majority of ophthalmology disorders, there are a number of premium products that attract substantial revenues – in particular Eylea, Lucentis, Lumigan and Restasis. The report focuses on five key indications within ophthalmology: glaucoma, age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy and dry eye syndrome. There are currently no therapeutic options available for the treatment of dry AMD, increasing the need for extensive R&D within this area.

Browse Detail Report With TOC @
http://www.hexareports.com/report/global-ophthalmology-drugs-market-to-2022

Although there is a high degree of failure and uncertainty within the R&D of ophthalmology drugs, the number of drugs in the pipeline is very high, at 734. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. This shows progression in terms of the variety of different molecules being developed as therapeutic agents within the ophthalmology pipeline. The expected growth of the ophthalmology market over the forecast period is attributed to the approval of new drugs, as well as rising prevalence.

Scope
* Global revenues for the ophthalmology market are forecast to grow at a compound annual growth rate of 9.48%, from $13.7 billion in 2015 to $26 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
* The ophthalmology pipeline is large and diverse, and contains 734 products. How does the composition of the pipeline compare with that of the existing market?
* What mechanisms of action and molecule types are most commonly being trialed in pipeline products in the various key indications?
* Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
* Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?

Request A Sample copy of This Report @
http://www.hexareports.com/report/global-ophthalmology-drugs-market-to-2022/request-sample

Reasons to buy

This report will allow you to -
1. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
2. Visualize the composition of the ophthalmology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
3. Analyze the ophthalmology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
4. Understand the growth in patient epidemiology and market revenues for the ophthalmology market, globally and across the key players and product types
5. Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various ophthalmology disorders.
6. Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Ophthalmology Drug Development Pipeline Review, 2016 -
http://www.hexareports.com/report/ophthalmology-drug-development-pipeline-review-2016

• COPD Therapeutics in Asia-Pacific Markets to 2022 -
http://www.hexareports.com/report/copd-therapeutics-in-asia-pacific-markets-to-2022

• Dermatology Therapeutics Drug Development Pipeline Review, 2016 -
http://www.hexareports.com/report/dermatology-therapeutics-drug-development-pipeline-review-2016

Immunology Market Development Trends, Economic Impacts and Market Forecasts to 2022

Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and loss of mobility, and have a negative impact on quality of life.

This disease area has a total of 2,145 products in active development, trailing only oncology, infectious diseases and central nervous system disorders in terms of pipeline size. There are a total of 529 immunology pipeline products that act on first-in-class molecular targets, representing approximately 40% of the total immunology pipeline for which the molecular target was disclosed.

Due to a degree of crossover between immunology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications.

Browse Detail Report With TOC @
http://www.hexareports.com/report/frontier-pharma-versatile-innovation-in-immunology

Approximately one-fifth of first-in-class pipeline products are in development for two or more indications within the therapy area. This presents an opportunity for companies to develop innovative products across multiple immune disorders, and therefore reach a larger pool of patients than products developed for single indications.

Scope
* What are the key points of overlap in the pathophysiology of immune disorders?
* What is the current standard of treatment across these markets, and what lessons can be learned by companies seeking to innovate and build on these products?
* Which molecule types and molecular targets are most prominent within the pipeline?
* Which first-in-class targets are most promising?
* Do immunology products attract high deal values, and which specific product types are able to attract the highest values?
* Which molecule types and molecular targets dominate the deals landscape?

Request A Sample copy of This Report @ http://www.hexareports.com/report/frontier-pharma-versatile-innovation-in-immunology/request-sample

Reasons to buy
1. Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.
2. Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the market.
3. Review key pipeline trends by analyzing therapies by stage of development, molecule type and molecular target, and identify key trends regarding innovation within each segment.
4. Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the immunology pipeline have been assessed and ranked according to clinical potential, and the most promising early-stage targets have been further reviewed in greater detail.
5. Identify promising first-in-class pipeline assets that have had no prior involvement in licensing or co-development deals, and are therefore potentially suitable for in-licensing.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Frontier Pharma: Head and Neck Cancer -
http://www.hexareports.com/report/frontier-pharma-head-and-neck-cancer

• Frontier Pharma: Melanoma Therapeutics-Cytokine and Multiple Targeted Small Molecules -
http://www.hexareports.com/report/frontier-pharma-melanoma-therapeutics-cytokine-and-multiple-targeted-small-molecules

• Influenza Therapeutics in Asia-Pacific Markets to 2022 -
http://www.hexareports.com/report/seasonal-influenza-therapeutics-in-asia-pacific-markets-to-2022

Rheumatoid Arthritis Market Provide Report Guidance for Pipeline Review, Products and Forecasts to 2022

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium – the soft tissue of the joint – leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3-1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.

Browse Detail Report With TOC @
http://www.hexareports.com/report/frontier-pharma-rheumatoid-arthritis

Scope
* Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.
* What is the pathophysiology of RA?
* Which products and therapeutic strategies dominate the clinical and commercial landscapes?
* What are the most significant unmet needs within the RA market?
* Considerable diversification from current market trends is evident within the RA pipeline.
* Which molecular targets are most prominent within the pipeline?
* What proportion of pipeline products are first in class?
* Which first-in-class targets are most promising?

 
Request A Sample copy of This Report @
http://www.hexareports.com/report/frontier-pharma-rheumatoid-arthritis/request-sample

Reasons to buy

This report will allow you to -
1. Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.
2. Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.
3. Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
4. Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the RA pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
5. Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Parkinson’s Disease – Heat Map and Analysis -
http://www.hexareports.com/report/parkinsons-disease-heat-map-and-analysis

• Non-Hodgkin Lymphoma – Heat Map and Analysis -
http://www.hexareports.com/report/non-hodgkin-lymphoma-heat-map-and-analysis

• Frontier Pharma: Versatile Innovation in Immunology -
http://www.hexareports.com/report/frontier-pharma-versatile-innovation-in-immunology

COPD Therapeutics Market Dynamics, Economic Impact, Status and Key Manufacture Analysis to 2022

Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. COPD occurs most often in older people, but can also affect people in their middle ages. It is a major cause of chronic morbidity and mortality globally. Many people suffer from this disease for years, and die from it or its complications, and it constitutes a substantial economic and social burden.

Globally, the COPD burden is projected to increase in the coming decades because of continued exposure to COPD risk factors, and the increasing number of smokers. Increased smoking will result in a greater number of people living with the condition, thereby acting as a driver for revenue growth. The share of mortality attributed to COPD is expected to increase in the coming decades, when compared with other chronic diseases such as heart disease and stroke.

Browse Detail Report With TOC @ http://www.hexareports.com/report/copd-therapeutics-in-asia-pacific-markets-to-2022

The marketed products landscape comprises a wide range of treatment options, including bronchodilator combinations, bronchodilator and ICS combinations, bronchodilator monotherapies and PDE-4 inhibitors. However, the market is undergoing a gradual transition, away from bronchodilator and ICS therapies and towards targeted and triple combination drug treatments. The market is set to be driven by recently launched products, and the approval of novel drugs that will supplement current market leaders and offer greater therapeutic options.

Request A Sample copy of This Report @ http://www.hexareports.com/report/copd-therapeutics-in-asia-pacific-markets-to-2022/request-sample

Scope
* The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%.
* Bronchodilators and ICS dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the COPD market?
* Do branded therapies show continuous growth, and are they facing any competition from generics?
* How will branded therapies be affected by upcoming pipeline therapies?
* The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
* Which molecular targets appear most frequently in the pipeline?
* Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
* What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?

Reasons to buy

This report will allow you to -
1. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
2. Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
3. Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
4. Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.


Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Global Respiratory Complications Therapeutics Market to 2022 -
http://www.hexareports.com/report/global-respiratory-complications-therapeutics-market-to-2022

• Colorectal Cancer – Heat Map and Analysis -
http://www.hexareports.com/report/colorectal-cancer-heat-map-and-analysis

• Global Antibacterial Drugs Market to 2022 -
http://www.hexareports.com/report/global-antibacterial-drugs-market-to-2022